(Q37401812)

20 August 2017

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells (English)

1 reference

20 August 2017

phase II clinical trial

0 references

0 references

0 references

0 references

20

Christof von Kalle

0 references

Janet L. Macpherson

object named as

Janet L Macpherson

28

0 references

John M. Murray

object named as

John M Murray

19

0 references

author name string

Ronald T Mitsuyasu

1

1 reference

20 August 2017

Thomas C Merigan

2

1 reference

20 August 2017

Andrew Carr

3

1 reference

20 August 2017

Jerome A Zack

4

1 reference

20 August 2017

Mark A Winters

5

1 reference

20 August 2017

Cassy Workman

6

1 reference

20 August 2017

Mark Bloch

7

1 reference

20 August 2017

Jacob Lalezari

8

1 reference

20 August 2017

Stephen Becker

9

1 reference

20 August 2017

Lorna Thornton

10

1 reference

20 August 2017

Bisher Akil

11

1 reference

20 August 2017

Homayoon Khanlou

12

1 reference

20 August 2017

Robert Finlayson

13

1 reference

20 August 2017

Robert McFarlane

14

1 reference

20 August 2017

Don E Smith

15

1 reference

20 August 2017

Roger Garsia

16

1 reference

20 August 2017

David Ma

17

1 reference

20 August 2017

Matthew Law

18

1 reference

20 August 2017

Julie A Ely

21

1 reference

20 August 2017

Sharon M Patino

22

1 reference

20 August 2017

Alison E Knop

23

1 reference

20 August 2017

Philip Wong

24

1 reference

20 August 2017

Alison V Todd

25

1 reference

20 August 2017

Margaret Haughton

26

1 reference

20 August 2017

Caroline Fuery

27

1 reference

20 August 2017

Geoff P Symonds

29

1 reference

20 August 2017

Louise A Evans

30

1 reference

20 August 2017

Susan M Pond

31

1 reference

20 August 2017

David A Cooper

32

1 reference

20 August 2017

language of work or name

English

0 references

publication date

15 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

15

1 reference

20 August 2017

3

1 reference

20 August 2017

285-292

1 reference

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

The challenge of HIV-1 subtype diversity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Intracellular antibodies (intrabodies) and their therapeutic potential

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Genetic therapies against HIV.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

CD4+ count-guided interruption of antiretroviral treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Gene transfer in humans using a conditionally replicating lentiviral vector

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Gene therapy for HIV infection: what does it need to make it work?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Current status of gene therapy strategies to treat HIV/AIDS.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

The application of ribozymes to HIV infection.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Gene therapy using hematopoietic stem cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Ribozyme therapy for HIV infection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Ribozymes in gene therapy of HIV-1.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Preclinical characterization of an anti-tat ribozyme for therapeutic application

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Retroviral delivery and anti-HIV testing of hammerhead ribozymes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Gene therapy. Intracellular immunization

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Ribozymes as potential anti-HIV-1 therapeutic agents.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR).

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Supplemental guidance on testing for replication-competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768566

Transgenic enrichment of cardiomyocytes from human embryonic stem cells

2 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNM.1932

Ribozymes: use as anti-HIV therapeutic molecules

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/19219022

12 December 2020

Sustained decrease of peripheral lymphocytes after allogeneic blood stem cell aphereses

1 reference

https://pubmed.ncbi.nlm.nih.gov/19219022

12 December 2020

Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/19219022

12 December 2020

Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19219022

12 December 2020

Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19219022

12 December 2020

Identifiers

DOI

10.1038/NM.1932

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19219022

1 reference